Forxiga approved in EU for chronic kidney disease treatment

Forxiga’s approval, based on unprecedented Phase III data, is the most significant advancement in chronic kidney disease (CKD) treatment in over 20 years.


AstraZeneca’s Forxiga (dapagliflozin), a sodium-cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type 2 diabetes (T2D).

The approval by the European Commission (EC) is based on positive results from the DAPA-CKD Phase III trial and follows the recommendation for approval by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

“Today’s approval establishes dapagliflozin as the first SGLT2 inhibitor approved for the treatment of CKD regardless of diabetes status in the EU,” said Professor Hiddo Heerspink at the University Medical Center Groningen, Netherlands. “Based on the unprecedented results from the DAPA-CKD Phase III trial, dapagliflozin delays disease progression providing physicians a critical opportunity to improve the prognosis of patients with CKD.”

Executive Vice President of AstraZeneca BioPharmaceuticals R&D, Mene Pangalos added: “Today’s approval is an important milestone for Forxiga and has the potential to transform treatment for the millions of people living with CKD in the EU. While new medicines like Forxiga advance the standard of care, we are also committed to the prevention and early detection of this often debilitating and life-threatening disease.”

The DAPA-CKD Phase III trial demonstrated that Forxiga, on top of standard-of-care (SoC) treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, reduced the relative risk of worsening of renal function, onset of end-stage kidney disease (ESKD), or risk of cardiovascular (CV) or renal death by 39 percent (the primary composite endpoint), compared to placebo (absolute risk reduction [ARR] = 5.3 percent) in patients with CKD Stages 2-4 and elevated urinary albumin excretion.

Forxiga also significantly reduced the relative risk of death from any cause by 31 percent (ARR = 2.1 percent) compared to placebo. The safety and tolerability of Forxiga were consistent with the well-established safety profile of the medicine.

Forxiga was recently approved in the US for the treatment of CKD in adults with and without T2D and is currently under review in Japan and several other countries around the world. Forxiga is also indicated as an adjunct to diet and exercise to improve glycaemic control in adults with T2D and for the treatment of symptomatic chronic heart failure (HF) with reduced ejection fraction (HFrEF) in adults regardless of diabetes status.